ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/a-biomarker-study-to-validate-predictors-for-clinical-outcome-of-cetuximab-based-chemotherapy-in-first-line-metastatic-colorectal-cancer-mcrc-pat
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis ... 5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/matrix-metalloproteinase-mediated-regulation-of-programmed-death-ligand-in-the-human-head-and-neck-squamous-cell-carcinoma-microenvironment
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/ctdna-assays-identify-alterations-in-ras-egfr-and-cmet-that-are-unique-to-ras-wt-patients-progressing-on-anti-egfr-therapy
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/prognostic-significance-of-lymphocyte-activation-gene-3-expression-in-chemoradiotherapy-naive-esophageal-and-gastric-adenocarcinoma
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
The median PFS was 3.7 (95% CI, 2.5-not computable) in poor prognosis group, 8.3 (95% CI, 6.0-30.0) in intermediate-bad, 18.4 ( ... 5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ... 95% CI, 14.3-23.6) in intermediate-good, and 37.1 months (95% CI, 30.8-53.5) in good prognosis group. Ki67% (continuous ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/development-and-internal-validation-of-a-predictive-nomogram-of-progression-free-survival-in-well-differentiated-stage-iv-gastroenteropancreatic-ne
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple ... sPD-L1 was elevated in advance acral and mucosal melanoma patients and may play an important role in patients prognosis. ... 5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... This study was designed to evaluate the association between circulating sPD-L1 expression and prognosis in patients with ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/soluble-pd-l1-as-a-prognostic-factor-in-advanced-acral-and-mucosal-melanoma
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ... However, when relapsing without surgical or reirradiation options, NPC carries a dismal prognosis; survival >2 years being ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/long-lasting-responses-to-adoptive-t-cell-therapy-in-relapsed-ebv-related-nasopharyngeal-carcinoma
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/discordance-between-her2-expression-status-in-primary-tumor-and-matched-malignant-ascites-in-gastric-adenocarcinoma
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
3833 - Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma. Presenter ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Multiple-primary-cancers-MPC-in-a-series-of-lung-cancer-LC-patient-incidence-and-outcome
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
4499 - Association of PD-L1 expression with prognosis among patients with 10 select cancers. Presenter: Torben Steiniche ... 5075 - Association of PD-L1 expression with prognosis among patients with 10 select cancers. Presenter: Laurie Gay ... 4788 - Tumor mutational burden and prognosis across pan-cancers. Presenter: Hao Ding ... 5155 - Tumor mutational burden and prognosis across pan-cancers. Presenter: Alberto Puccini ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/analytic-validation-of-tumor-mutational-burden-as-a-companion-diagnostic-for-combination-immunotherapy-in-non-small-cell-lung-cancer
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
Patients with a good response to PT for first recurrence also had significantly better prognosis, regardless of ET or ... or first recurrence without liver metastasis had a significantly better prognosis (p < 0.001, p = 0.007, and p < 0.001, ... we identify the significant factors correlating to prognosis in a retrospective study. Recognizing the prognostic factors for ... more optimal treatment to first recurrence could improve drug resistance and eventually lead to better prognosis. ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/response-to-primary-treatment-for-first-recurrence-independently-influences-survival-of-patients-with-hormone-receptor-positive-her2-negative-brea
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/the-impact-of-inclusion-in-home-palliative-program-and-distance-to-hospital-on-chemotherapy-near-end-of-life?page=2
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/the-role-of-modulation-of-somatostatin-analogues-ssas-in-association-to-peptide-receptor-radionuclide-therapy-prrt-after-ssas-progression-disea
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/pd-l1-expression-and-t-cell-inflamed-gene-expression-profile-gep-in-korean-and-us-patients-pts-with-advanced-gastric-cancer-gc
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... Presence of epithelioid cells with high melanin pigmentation leads to worse patients prognosis. Non-canonical NFκB (NC-NFκB) ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/activation-of-non-canonical-nf_b-nc-nf_b-pathway-in-inflammatory-environment-of-uveal-melanoma
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/withholding-anti-egfr-impact-on-outcome-of-ras-wild-type-metastatic-colorectal-tumors-wait-or-act-a-multicentric-ageo-study
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/a-phase-ii-trial-of-gemcitabine-s-1-and-lv-combination-therapy-in-patients-with-advanced-pancreatic-cancer
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/outcomes-by-prior-transarterial-chemoembolization-tace-in-the-phase-3-celestial-trial-of-cabozantinib-c-versus-placebo-p-in-patients-pts-wi
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/treatment-pattern-and-outcomes-of-trifluridine-tipiracil-therapy-for-metastatic-colorectal-cancer-in-the-real-world-data-from-the-jfmc50-study
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/phase-ii-trial-to-evaluate-efficacy-and-tolerance-of-regorafenib-monotherapy-in-patients-pts-over-70-with-previously-treated-metastatic-colorecta
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/morphologic-response-to-chemotherapy-containing-bevacizumab-in-patients-with-colorectal-liver-metastases-clm-a-post-hoc-analysis-of-the-wjog4407
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
The purpose of the NADEGE cohort is to describe characteristics and prognosis of SBA in unselected patients (pts) at a ... 5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.. Presenter: Natalia Levitskaya ... 1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer ...
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/arcad-nadege-cohort-result-of-a-small-bowel-adenocarcinomas-prospective-cohort
ESMO Asia 2018 Congress | OncologyPROESMO Asia 2018 Congress | OncologyPRO
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
ESMO Asia 2018 Congress | OncologyPROESMO Asia 2018 Congress | OncologyPRO
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
ESMO 2018 Congress | OncologyPROESMO 2018 Congress | OncologyPRO
ESMO Asia 2018 Congress | OncologyPROESMO Asia 2018 Congress | OncologyPRO
ESMO 2019 Congress | OncologyPROESMO 2019 Congress | OncologyPRO
Current systemic treatments with targeted therapy and immunotherapy prolong survival up to > 2 years, while prognosis of BMs ...
https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/the-analysis-of-current-treatment-outcomes-in-melanoma-patients-with-brain-metastases?page=2